Skip to content
DataLookout
Menu

NCT06067555

Intradermal Influenza Vaccination- Healthy Cohort

StatusCompleted
PhaseEarly Phase 1
Primary completion
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 8 versions: 7 with changes below, 1 re-verified with no change. See every version on ClinicalTrials.gov ↗

  1. Notable Eligibility criteria shortened, about 9 words Show 8 more changesShow less
    • Trial completed
    • Final enrollment: 42 participants (planned 249)
    • Primary completion date changed from estimate of May 2026 to Feb 26, 2025
    • Trial arms changed: 9 → 3
    • Study description shortened, about 49 words
    • Site details revised
    • Collaborators revised (4)
    • Study title expanded, about 2 words
  2. Minor Study description expanded, about 3 wordsv6
  3. Notable Trial status: Not Yet Recruiting to Recruiting
    • Start date changed from estimate of Jan 2024 to Jan 24, 2024
    • Site details revised
    • Collaborators: 2 to 4
    v5
  4. Minor Collaborators revised (2)v4
  5. Notable Eligibility criteria shortened, about 11 words
    • Start date: Dec 2023 to Jan 2024
    v3
  6. Notable Eligibility criteria expanded, about 58 wordsv2 Show 7 more changesShow less
    • Enrollment target: 250 to 249
    • Primary and study completion dates: Jan 2026 to May 2026
    • Start date: Nov 2023 to Dec 2023
    • Interventions: Fluzone® Quadrivalent (Biological), Fluzone® Quadrivalent (Biological), MicronJet (Device) to Bacteriostatic Saline (Other), Fluzone® Quadrivalent (Biological), Fluzone® Quadrivalent (Biological), MicronJet (Device)
    • Study description shortened, about 7 words
    • Collaborators: 1 to 2
    • Study arms: 5 to 9
  7. Study First Submitted
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Change in antibody titer concentration to vaccination-Blood
Timeframe: Day 0 and Day 28
Change in antibody titer concentration to vaccination-Skin
Timeframe: Day 0 and Day 28

Secondary (1)

Change in antibody titer concentration to vaccination

Arms and interventions

Intradermal salinePlacebo comparator

Healthy participants will receive intradermal saline injection.

Intradermal flu vaccineActive comparator

Healthy participants will receive intradermal flu vaccine injection.

Intramuscular fluExperimental

Healthy participants will receive intramuscular flu vaccine injection.

Devices: MicronJet

Biologicals: Fluzone® Quadrivalent

Other: Bacteriostatic Saline

Sites

1 site in 1 country

  • Church Street Research UnitNew Haven, Connecticut, United States